US durable goods orders down 3.7 percent in January

WASHINGTON — New orders for long-lasting manufactured goods fell 3.7 percent in January, the biggest decline since July 2017, following two months of increases that reflected strength in the country's industry.

The Commerce Department said Tuesday that orders were depressed by a 10 percent drop in demand for transportation equipment, a category that can bounce around from month to month. Excluding transportation, durable goods orders slipped only 0.3 percent. Orders for defense capital goods plunged 26.3 percent. Excluding defense, new durable goods orders fell 2.7 percent.

Overall orders in January for durable goods, which are meant to last at least three years, decreased 3.7 percent to $239.7 billion. Orders were up 5.8 percent for the full year 2017, the best showing in six years.

American manufacturers have benefited from a pickup in global economic growth and a weaker dollar, which makes U.S. goods less expensive in foreign markets.


—The Commerce Department downgraded the December increase in durable goods orders to 2.6 percent from the 2.9 percent gain it originally reported.

—January orders for computers increased 6.4 percent after falling 4.9 percent in December.

—Machinery orders fell 0.4 percent after gaining 0.5 percent the previous month.

Must Read

Bolt advances, Russian qualifies and an engagement at track

Aug 17, 2016

The midpoint of the nine-day track and field program at Olympic Stadium was a day for diamond rings and making friends, a rare Russian hello and a surprising Brazilian farewell

Global stocks dip ahead of release of Fed minutes

Aug 17, 2016

Global stocks and the price of oil dipped Wednesday as investors awaited the release of the minutes to the Federal Reserve's latest meeting for hints on when the next interest rate increase might come

Patent for J&J's Remicade invalidated, cheaper version looms

Aug 17, 2016

A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid


Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: